The treatment landscape of Waldenström macroglobulinemia is becoming increasingly complex with second-generation BTK inhibitors; however, the combination of bendamustine and rituximab remains the frontline standard of care for this patient population.
Immune therapy has evolved rapidly in multiple myeloma, and the field is on the verge of major improvements in outcomes.
Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.
Several options have emerged for patients with acute myeloid leukemia who are not candidates to receive chemotherapy, with venetoclax-based regimens chief among them.
Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.
Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Rituximab plus CHOP is not a suitable frontline treatment regimen for all patients with diffuse large B-cell lymphoma, explained Andre H. Goy, MD, who specified that patients with a high-risk International Prognostic Index, elderly patients, and patients with high-risk molecular subtypes require alternative treatment.
CD19-targeted CAR T-cell therapies have yielded durable remissions in approximately half of all patients with aggressive relapsed/refractory B-cell lymphomas.
Treatment with chimeric antigen receptor T cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.
Since the publication of the pivotal ELIANA trial in pediatric patients with acute lymphoblastic leukemia, the field of CAR T-cell therapy has grown significantly and left providers better equipped to understand and manage treatment-related adverse effects, such as cytokine release syndrome.
Andrew Ip, MD, MS, discusses the challenges of treating patients with hematologic malignancies and COVID-19.
Carlos del Rio, MD, discusses factors to consider when selecting between available vaccines for COVID-19.
February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.
February 13, 2021 - Cabozantinib resulted in a statistically significant and clinically meaningful prolongation of progression-free survival compared with sunitinib in patients with metastatic papillary renal cell carcinoma.
February 13, 2021 - Lenvatinib in combination with pembrolizumab resulted in improved overall survival, progression-free survival, and objective response rate over sunitinib in the frontline treatment of patients with advanced renal cell carcinoma.
February 13, 2021 - Belzutifan used in combination with cabozantinib shrank tumors for 88% of patients and the disease control rate was 90% for patients with previously treated advanced clear cell renal cell carcinoma.
February 13, 2021 - Certain molecular signatures at baseline were found to be independently linked with long-term response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.
February 13, 2021 - Bacillus calmette-guérin plus N-803 demonstrated promising responses with a tolerable safety profile when used in patients with BCG-unresponsive, non–muscle-invasive bladder cancer carcinoma in situ
February 13, 2021 - Reductions in prostate-specific antigen screening are likely responsible for the recent increase in metastatic prostate cancer cases in the United States.
February 13, 2021 - 18F-DCFPyL, an investigational prostate-specific membrane antigen PET imaging agent, was found to detect and localize metastatic lesions with a high correct localization rate and positive predictive value.
Patrick Pilie, MD, discusses the impact of adiposity on response to androgen signaling inhibition in patients with metastatic castration-resistant prostate cancer.
Tanya Dorff, MD, discusses the effects of bright white light therapy on obese frailty in older men with prostate cancer.
February 13, 2021 - Enfortumab vedotin was found to have superior efficacy over chemotherapy when used in patients with advanced urothelial carcinoma who had received prior platinum-based chemotherapy and PD-1/L1 inhibition.
February 13, 2021 - Treatment with apalutamide plus androgen-deprivation therapy reduced the risk of death by 35% versus ADT alone in patients with metastatic castration-sensitive prostate cancer.
February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.
February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
February 12, 2021 - Cabozantinib demonstrated significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma who have brain metastases.
Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.
Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
